viewSilence Therapeutics PLC

Silence Therapeutics - Notice of AGM

RNS Number : 1966M
Silence Therapeutics PLC
07 May 2020

Silence Therapeutics Notice of Annual General Meeting


May 7, 2020


LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that this year's Annual General Meeting ("AGM") of the Company will be held on 9 June 2020 at 10:00am. The AGM will be held at Herons Ghyll, Tilford Road, Tilford, Surrey GU10 2DD.


The Notice of the AGM will be posted to shareholders today, 7 May 2020, when it will also be made available on the Company's website.


To comply with the UK Government's Stay at Home measures, shareholders will not be allowed to attend the meeting in person. Shareholders are strongly encouraged to therefore submit their votes, in respect of all matters of business, via proxy as early as possible. They should appoint the Chairman of the meeting as their proxy. If the situation changes then shareholders will be notified via the Company's website at https://www.silence-therapeutics.com and via RNS announcement.





Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer

Tel:  +44 (0)20 3457 6900



Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson


Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh/ Angela Gray

[email protected]


Tel: +44 (0) 20 3709 5700


Westwicke Partners

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505



About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Silence Therapeutics PLC

Price: 464

Market: AIM
Market Cap: £384.31 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Silence Therapeutics feels move to NASDAQ will give its tech the...

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq. Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies...

on 22/5/20